High Caveolin-1 mRNA expression in triple-negative breast cancer is associated with an aggressive tumor microenvironment, chemoresistance, and poor clinical outcome.

<h4>Background</h4>Currently, there are few treatment-predictive and prognostic biomarkers in triple-negative breast cancer (TNBC). Caveolin-1 (CAV1) is linked to chemoresistance and several important processes involved in tumor progression and metastasis, such as epithelial-mesenchymal...

Full description

Saved in:
Bibliographic Details
Main Authors: Christopher Godina, Somayeh Khazaei, Mattias Belting, Johan Vallon-Christersson, Björn Nodin, Karin Jirström, Karolin Isaksson, Ana Bosch, Helena Jernström
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2024-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0305222
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849731259414085632
author Christopher Godina
Somayeh Khazaei
Mattias Belting
Johan Vallon-Christersson
Björn Nodin
Karin Jirström
Karolin Isaksson
Ana Bosch
Helena Jernström
author_facet Christopher Godina
Somayeh Khazaei
Mattias Belting
Johan Vallon-Christersson
Björn Nodin
Karin Jirström
Karolin Isaksson
Ana Bosch
Helena Jernström
author_sort Christopher Godina
collection DOAJ
description <h4>Background</h4>Currently, there are few treatment-predictive and prognostic biomarkers in triple-negative breast cancer (TNBC). Caveolin-1 (CAV1) is linked to chemoresistance and several important processes involved in tumor progression and metastasis, such as epithelial-mesenchymal transition (EMT). Herein, we report that high CAV1 gene expression is an independent factor of poor prognosis in TNBC.<h4>Methods</h4>CAV1 gene expression was compared across different molecular features (e.g., PAM50 subtypes). CAV1 expression was assessed in relation to clinical outcomes using Cox regression adjusted for clinicopathological predictors. Differential gene expression and gene set enrichment analyses were applied to compare high- and low-expressing CAV1 tumors. Tumor microenvironment composition of high- and low-expressing CAV1 tumors was estimated using ECOTYPER. Tumor tissue microarrays were used to evaluate CAV1 protein levels in stromal and malignant cells.<h4>Results</h4>In the SCAN-B (n = 525) and GSE31519 (n = 327) cohorts, patients with CAV1-high tumors had an increased incidence of early recurrence adjusted HR 1.78 (95% CI 1.12-2.81) and 2.20 (95% CI 1.39-3.47), respectively. In further analysis, high CAV1 gene expression was associated with a molecular profile indicating altered metabolism, neovascularization, chemoresistance, EMT, suppressed immune response, and active tumor microenvironment. Protein levels of CAV1 in malignant and stromal cells were not correlated with CAV1 gene expression.<h4>Conclusion</h4>CAV1 gene expression in TNBC is a biomarker that merits further investigation in clinical trials and as a therapeutic target.
format Article
id doaj-art-b8af823829db42e29aa5801ab12f0df5
institution DOAJ
issn 1932-6203
language English
publishDate 2024-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj-art-b8af823829db42e29aa5801ab12f0df52025-08-20T03:08:36ZengPublic Library of Science (PLoS)PLoS ONE1932-62032024-01-01197e030522210.1371/journal.pone.0305222High Caveolin-1 mRNA expression in triple-negative breast cancer is associated with an aggressive tumor microenvironment, chemoresistance, and poor clinical outcome.Christopher GodinaSomayeh KhazaeiMattias BeltingJohan Vallon-ChristerssonBjörn NodinKarin JirströmKarolin IsakssonAna BoschHelena Jernström<h4>Background</h4>Currently, there are few treatment-predictive and prognostic biomarkers in triple-negative breast cancer (TNBC). Caveolin-1 (CAV1) is linked to chemoresistance and several important processes involved in tumor progression and metastasis, such as epithelial-mesenchymal transition (EMT). Herein, we report that high CAV1 gene expression is an independent factor of poor prognosis in TNBC.<h4>Methods</h4>CAV1 gene expression was compared across different molecular features (e.g., PAM50 subtypes). CAV1 expression was assessed in relation to clinical outcomes using Cox regression adjusted for clinicopathological predictors. Differential gene expression and gene set enrichment analyses were applied to compare high- and low-expressing CAV1 tumors. Tumor microenvironment composition of high- and low-expressing CAV1 tumors was estimated using ECOTYPER. Tumor tissue microarrays were used to evaluate CAV1 protein levels in stromal and malignant cells.<h4>Results</h4>In the SCAN-B (n = 525) and GSE31519 (n = 327) cohorts, patients with CAV1-high tumors had an increased incidence of early recurrence adjusted HR 1.78 (95% CI 1.12-2.81) and 2.20 (95% CI 1.39-3.47), respectively. In further analysis, high CAV1 gene expression was associated with a molecular profile indicating altered metabolism, neovascularization, chemoresistance, EMT, suppressed immune response, and active tumor microenvironment. Protein levels of CAV1 in malignant and stromal cells were not correlated with CAV1 gene expression.<h4>Conclusion</h4>CAV1 gene expression in TNBC is a biomarker that merits further investigation in clinical trials and as a therapeutic target.https://doi.org/10.1371/journal.pone.0305222
spellingShingle Christopher Godina
Somayeh Khazaei
Mattias Belting
Johan Vallon-Christersson
Björn Nodin
Karin Jirström
Karolin Isaksson
Ana Bosch
Helena Jernström
High Caveolin-1 mRNA expression in triple-negative breast cancer is associated with an aggressive tumor microenvironment, chemoresistance, and poor clinical outcome.
PLoS ONE
title High Caveolin-1 mRNA expression in triple-negative breast cancer is associated with an aggressive tumor microenvironment, chemoresistance, and poor clinical outcome.
title_full High Caveolin-1 mRNA expression in triple-negative breast cancer is associated with an aggressive tumor microenvironment, chemoresistance, and poor clinical outcome.
title_fullStr High Caveolin-1 mRNA expression in triple-negative breast cancer is associated with an aggressive tumor microenvironment, chemoresistance, and poor clinical outcome.
title_full_unstemmed High Caveolin-1 mRNA expression in triple-negative breast cancer is associated with an aggressive tumor microenvironment, chemoresistance, and poor clinical outcome.
title_short High Caveolin-1 mRNA expression in triple-negative breast cancer is associated with an aggressive tumor microenvironment, chemoresistance, and poor clinical outcome.
title_sort high caveolin 1 mrna expression in triple negative breast cancer is associated with an aggressive tumor microenvironment chemoresistance and poor clinical outcome
url https://doi.org/10.1371/journal.pone.0305222
work_keys_str_mv AT christophergodina highcaveolin1mrnaexpressionintriplenegativebreastcancerisassociatedwithanaggressivetumormicroenvironmentchemoresistanceandpoorclinicaloutcome
AT somayehkhazaei highcaveolin1mrnaexpressionintriplenegativebreastcancerisassociatedwithanaggressivetumormicroenvironmentchemoresistanceandpoorclinicaloutcome
AT mattiasbelting highcaveolin1mrnaexpressionintriplenegativebreastcancerisassociatedwithanaggressivetumormicroenvironmentchemoresistanceandpoorclinicaloutcome
AT johanvallonchristersson highcaveolin1mrnaexpressionintriplenegativebreastcancerisassociatedwithanaggressivetumormicroenvironmentchemoresistanceandpoorclinicaloutcome
AT bjornnodin highcaveolin1mrnaexpressionintriplenegativebreastcancerisassociatedwithanaggressivetumormicroenvironmentchemoresistanceandpoorclinicaloutcome
AT karinjirstrom highcaveolin1mrnaexpressionintriplenegativebreastcancerisassociatedwithanaggressivetumormicroenvironmentchemoresistanceandpoorclinicaloutcome
AT karolinisaksson highcaveolin1mrnaexpressionintriplenegativebreastcancerisassociatedwithanaggressivetumormicroenvironmentchemoresistanceandpoorclinicaloutcome
AT anabosch highcaveolin1mrnaexpressionintriplenegativebreastcancerisassociatedwithanaggressivetumormicroenvironmentchemoresistanceandpoorclinicaloutcome
AT helenajernstrom highcaveolin1mrnaexpressionintriplenegativebreastcancerisassociatedwithanaggressivetumormicroenvironmentchemoresistanceandpoorclinicaloutcome